当前位置: 首页 > 期刊 > 《中国医学创新》 > 202015
编号:13477125
SR蛋白家族对肿瘤发生发展影响的研究进展(5)
http://www.100md.com 2020年5月25日 《中国医学创新》 202015
     [26] Long J,Caceres J.The SR protein family of splicing factors:master regulators of gene expression[J].Biochemical Journal,2009,417(1):15.

    [27] Das S,Olga Anczuków,Akerman M,et al.Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYC[J].Cell Reports,2012,1(2):110-117.

    [28] Cohen-Eliav M,Golan-Gerstl R,Siegfried Z,et al.The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers[J].The Journal of Pathology,2013,229(4):630-639.

    [29] Luo C,Cheng Y,Liu Y,et al.SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development[J].Cancer Research,2017,77(5):1168-1178.

    [30] Xu X,Yang D,Ding J H,et al.ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle[J].Cell,2005,120(1):59-72.

    [31] Wang H Y,Xu X,Ding J H,et al.SC35 plays a role in T cell development and alternative splicing of CD45[J].Mol Cell,2001,7(2):331-342.

    [32] Cheng Y,Luo C,Wu W,et al.Liver-specific deletion of SRSF2 caused acute liver failure and early death in mice[J].Molecular and Cellular Biology,2016,36(11):MCB.01071-15.

    [33] Supriya S,Magda L,Hassan J,et al.Deletion of splicing factor SRSF3 in hepatocytes predisposes to hepatocellular carcinoma in mice[J].Hepatology,2015,61(1):171.

    (收稿日期:2019-11-07) (本文編辑:程旭然), 百拇医药(李梦仙 俞建昆 温艳萍 吴翰欣 高凌 刘晓晓 邰文琳)
上一页1 2 3 4 5